143 related articles for article (PubMed ID: 33378249)
1. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH; Tan E; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
[TBL] [Abstract][Full Text] [Related]
2. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
3. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract][Full Text] [Related]
4. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
Botrus G; Raman P; Oliver T; Bekaii-Saab T
Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
[TBL] [Abstract][Full Text] [Related]
5. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
Kim RD; Sanoff HK; Poklepovic AS; Soares H; Kim J; Lyu J; Liu Y; Nixon AB; Kim DW
Cancer; 2020 Aug; 126(15):3464-3470. PubMed ID: 32453456
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
[TBL] [Abstract][Full Text] [Related]
8. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
10. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
Sipra QUAR; Shroff R
Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
[No Abstract] [Full Text] [Related]
11. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
Lee YC; Michael M; Zalcberg JR
Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
[TBL] [Abstract][Full Text] [Related]
12. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
Chan SL; Ma BB
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
[TBL] [Abstract][Full Text] [Related]
13. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.
Marin JJ; Macias RI
Expert Opin Investig Drugs; 2021 Jul; 30(7):675-679. PubMed ID: 33934687
[No Abstract] [Full Text] [Related]
14. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
[No Abstract] [Full Text] [Related]
15. Cholangiocarcinoma: investigations into pathway-targeted therapies.
Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
[TBL] [Abstract][Full Text] [Related]
16. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
17. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
18. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials.
Bourien H; Lamarca A; McNamara MG; Hubner RA; Valle JW; Edeline J
Expert Opin Investig Drugs; 2021 Sep; 30(9):975-983. PubMed ID: 34420429
[No Abstract] [Full Text] [Related]
19. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Bengala C; Bertolini F; Malavasi N; Boni C; Aitini E; Dealis C; Zironi S; Depenni R; Fontana A; Del Giovane C; Luppi G; Conte P
Br J Cancer; 2010 Jan; 102(1):68-72. PubMed ID: 19935794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]